The *doctors have begun to prepare for the upcoming clinical trials in Belfast this August. ISEA, the International Symposium on Electronic Art will be the overall setting. For the month-long show “ISEA2009: The Exhibition,” curated by Kathy Rae Huffman at the Golden Thread Gallery we will have an ongoing portal with clinic hours to be posted. A medium-sized mobile walk in clinic will be set up during the conference days August 26th through 29th.
Test subject JC Priestman has been showing increased signs of transgenic mutations, including protruding facial features, large rounded ears and his tail elongation has increased. We are hoping our gene splice will eventually produce a good transgenic rat specimen. The doctors will continue to monitor and document the situation.
JC Priestman, who has been with the VF clinical trials from the start, is beginning to show troubling signs of VF addiction. He has been seen hanging out around the clinic after hours and the inventory in the pharmacy seems to be out of order. Although he is understandably tired after his contribution, his demeanor seems to have changed and he spends may hours facing into corners of rooms with a glazed, detached expression.
JC Priestman Showing Signs of VF Addiction
The effectiveness of the use of VF in the treatment of internet addiction is still unclear, but we fear that VF might cause its own dependancy issues.
The Virta-Flaneurazine clinic opened on Saturday, September 6, 2008. We have begun to compile and document the early trial results.
The latest issue of VF Magazine is available. The clinic will provide issues for reading material in the waiting area.
VF Cover, September 6, 2008
Extremely slow performance in distant clinic operations has led the research team to experiment with remote temporal operation. The use of ARD’s sliding temporal shifts has allowed substantial performance increases at satellite clinic stations. Undoubtedly, temporal memory plays a significant role in every aspect of this study.
Remote Time Experiment 1bitmap
Our fastest results were achieved in the 1988 timeframe, but the lack of detail distinction, for all intent and purposes, made the data unusable.
Our initial test subject, JC Priestman, arrived at the clinic today for pre-trial screening.
MEMO #2008-06-20_032
To: Dr. willpap
From: Dr. johncraigfreeman
Re: Wanderlust Deficit Disorder
This is an internal memo intended for your eyes only. Please keep its contents confidential.
Given the disastrous results of the latest mice trials, the parent company and our investors have recommended a change of course in our research. They have asked us to consider redeveloping VF to target the lucrative recreational pharmaceutical market. In order to do this successfully, a malady must be identified, or created as the case may be, which VF can be reasonably seen to remedy.
After careful consideration. I propose that we focus on Wanderlust Deficit Disorder (WDD). We know that VF has shown promise in getting even the most flaccid internet addicts up and active, even if that activity is aimless or misdirected.
The parent company’s marketing department and our lobby consulting team agree that WDD could constitute a sizable market in coming years.
We have been asked to indicate this change of direction by changing the appearance of VF to include a more “happy-go-lucky” color scheme and sexier graphics.
Dr. Pomer, Dr. Fremont ask that I forward this very important memorandum to you as soon as possible. Please keep its contents confidential. JCF.
MEMO #2008-05-28_001
To: Dr. Pomer
From: Dr. Fremont
Re: Hippies congregate at VF Clinic
It seems that the recent congregation of hippies near the VF clinic is due, to some extent, to the proliferation of Bufotoads on the SIM. It seems that they have become somewhat accustom to spending their days licking the secretions from the escaped specimens. My first inclination was to run them off, as I found their drum circles to be distracting from the research duties at the clinic. Upon further reflection however, I believe these individuals might make unsuspecting test subjects when we are ready to begin our human trials.
|
johncraigfreeman
willpap
jcfremont
pomerpau2
